• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

磷脂和因子Va在凝血酶原酶复合物中的作用。

The role of phospholipids and factor Va in the prothrombinase complex.

作者信息

Rosing J, Tans G, Govers-Riemslag J W, Zwaal R F, Hemker H C

出版信息

J Biol Chem. 1980 Jan 10;255(1):274-83.

PMID:7350159
Abstract

The kinetic parameters of the conversion of bovine prothrombin into thrombin by activated bovine blood clotting factor X (Xa) have been determined in the absence and presence of Ca2+, activated bovine factor V (Va) and phospholipid (dioleoylphosphatidylcholine/dioleoylphosphatidylserine, 1:1; mol/mol). In the absence of accessory components, the Km for prothrombin is 131 microM, which is well above its concentration in bovine plasma of about 1.5 microM. The Vmax of thrombin formation is 0.61 mol min-1 mol of Xa-1 under these conditions. In the presence of 7.5 microM phospholipid, the Km drops to 0.058 microM and the Vmax slightly increases to 2.25 mol min-1 mol of Xa. For the complete prothrombinase complex (Xa, Va, Ca2+, and 7.5 microM phospholipid), a Km for prothrombin of 0.21 microM and a Vmax of 1919 mol min-1 mol of Xa-1 is found. The Vmax of thrombin formation slightly increases when more phospholipid is present in our experiments and there is a considerable increase of the Km for prothrombin at higher phospholipid concentrations. Preliminary calculations show that the prothrombin density at the phospholipid surface at the Km is independent of the phospholipid concentration. This indicates that the Km measured in the presence of phospholipid has to be regarded as an apparent Km and the local prothrombin concentration determines the kinetics of activation. Prothrombin activation by prothrombinase complexes of different compositions was followed by gel electrophoresis in the presence of sodium dodecyl sulfate. Both in the absence and presence of phospholipid but without factor Va, prethrombin 2 is the main product formed during the initial stages of steady state prothrombin activation. In the presence of factor Va, thrombin is the main end product and minute amounts of prethrombin 2 are formed. This shift in the reaction pathway of prothrombin activation caused by factor Va will contribute to the observed increase of the Vmax measured in the presence of factor Va.

摘要

在不存在和存在Ca2+、活化牛因子V(Va)和磷脂(二油酰磷脂酰胆碱/二油酰磷脂酰丝氨酸,1:1;摩尔/摩尔)的情况下,已测定了活化牛凝血因子X(Xa)将牛凝血酶原转化为凝血酶的动力学参数。在不存在辅助成分的情况下,凝血酶原的Km为131μM,远高于其在牛血浆中的浓度(约1.5μM)。在这些条件下,凝血酶形成的Vmax为0.61摩尔·分钟-1·摩尔Xa-1。在存在7.5μM磷脂的情况下,Km降至0.058μM,Vmax略有增加至2.25摩尔·分钟-1·摩尔Xa。对于完整的凝血酶原酶复合物(Xa、Va、Ca2+和7.5μM磷脂),发现凝血酶原的Km为0.21μM,Vmax为1919摩尔·分钟-1·摩尔Xa-1。在我们的实验中,当存在更多磷脂时,凝血酶形成的Vmax略有增加,并且在较高磷脂浓度下凝血酶原的Km有相当大的增加。初步计算表明,在Km时磷脂表面的凝血酶原密度与磷脂浓度无关。这表明在存在磷脂的情况下测得的Km必须被视为表观Km,局部凝血酶原浓度决定了活化动力学。在十二烷基硫酸钠存在下,通过凝胶电泳跟踪不同组成的凝血酶原酶复合物对凝血酶原的活化。在不存在和存在磷脂但没有因子Va的情况下,凝血酶原2是稳态凝血酶原活化初始阶段形成的主要产物。在存在因子Va的情况下,凝血酶是主要终产物,仅形成微量的凝血酶原2。因子Va引起的凝血酶原活化反应途径的这种转变将导致在存在因子Va时测得的Vmax增加。

相似文献

1
The role of phospholipids and factor Va in the prothrombinase complex.磷脂和因子Va在凝血酶原酶复合物中的作用。
J Biol Chem. 1980 Jan 10;255(1):274-83.
2
The role of phospholipid and factor VIIIa in the activation of bovine factor X.磷脂和凝血因子VIIIa在牛凝血因子X激活中的作用。
J Biol Chem. 1981 Apr 10;256(7):3433-42.
3
The contribution of bovine Factor V and Factor Va to the activity of prothrombinase.牛凝血因子V和凝血因子Va对凝血酶原酶活性的作用。
J Biol Chem. 1979 Nov 10;254(21):10952-62.
4
Factor Va-factor Xa interaction. Effects of phospholipid vesicles of varying composition.因子Va-因子Xa相互作用。不同组成的磷脂囊泡的影响。
Biochemistry. 1982 Oct 26;21(22):5494-502. doi: 10.1021/bi00265a018.
5
Contribution of the prothrombin fragment 2 domain to the function of factor Va in the prothrombinase complex.凝血酶原片段2结构域对凝血酶原酶复合物中因子Va功能的作用。
Biochemistry. 1997 Mar 18;36(11):3319-30. doi: 10.1021/bi9623993.
6
Kinetic studies of prothrombin activation: effect of factor Va and phospholipids on the formation of the enzyme-substrate complex.凝血酶原激活的动力学研究:因子Va和磷脂对酶-底物复合物形成的影响。
Biochemistry. 1984 Sep 25;23(20):4557-64. doi: 10.1021/bi00315a008.
7
Meizothrombin formation during factor Xa-catalyzed prothrombin activation. Formation in a purified system and in plasma.凝血因子Xa催化凝血酶原激活过程中中间凝血酶的形成。在纯化系统和血浆中的形成。
J Biol Chem. 1991 Nov 15;266(32):21864-73.
8
Activation of bovine factor V by an activator purified from the venom of Naja naja oxiana.由中亚眼镜蛇毒液中纯化的激活剂对牛凝血因子V的激活作用。
Toxicon. 1992 Sep;30(9):1065-79. doi: 10.1016/0041-0101(92)90052-7.
9
The prothrombinase-catalyzed activation of prothrombin proceeds through the intermediate meizothrombin in an ordered, sequential reaction.凝血酶原酶催化凝血酶原的激活在一个有序的顺序反应中通过中间产物中凝血酶进行。
J Biol Chem. 1986 Jul 5;261(19):8977-84.
10
Studies of the role of factor Va in the factor Xa-catalyzed activation of prothrombin, fragment 1.2-prethrombin-2, and dansyl-L-glutamyl-glycyl-L-arginine-meizothrombin in the absence of phospholipid.在无磷脂情况下,关于因子Va在因子Xa催化凝血酶原、1.2片段-凝血酶原-2及丹磺酰-L-谷氨酰-甘氨酰-L-精氨酸-前凝血酶原激活中作用的研究。
J Biol Chem. 1990 Jun 25;265(18):10497-505.

引用本文的文献

1
Reversible High-Affinity Binding of Coagulation Factor Xa to Zeolites Induces Accelerated Blood Coagulation.凝血因子Xa与沸石的可逆高亲和力结合可加速血液凝固。
Adv Sci (Weinh). 2025 Jun;12(22):e2417099. doi: 10.1002/advs.202417099. Epub 2025 Apr 11.
2
A Novel Human Anti-FV mAb as a Potential Tool for Diagnostic and Coagulation Inhibitory Approaches.一种新型人抗FV单克隆抗体作为诊断和凝血抑制方法的潜在工具。
Int J Mol Sci. 2025 Mar 18;26(6):2721. doi: 10.3390/ijms26062721.
3
A child with factor V deficiency with a novel F5 gene mutation misdiagnosed as a left iliac fossa abscess: A case report.
一名存在新型 F5 基因突变的因子 V 缺乏症患儿被误诊为左髂窝脓肿:一例报告。
Medicine (Baltimore). 2024 Nov 15;103(46):e40436. doi: 10.1097/MD.0000000000040436.
4
Activated protein C resistance in the copresence of emicizumab and activated prothrombin complex concentrates.在emicizumab和活化凝血酶原复合物浓缩剂同时存在的情况下活化蛋白C抵抗
Res Pract Thromb Haemost. 2024 Jun 18;8(4):102479. doi: 10.1016/j.rpth.2024.102479. eCollection 2024 May.
5
The Prothrombin-Prothrombinase Interaction.凝血酶原-凝血酶酶促复合物的相互作用。
Subcell Biochem. 2024;104:409-423. doi: 10.1007/978-3-031-58843-3_15.
6
Modeling the distribution of enzymes on lipid vesicles: A novel framework for surface-mediated reactions in coagulation.在脂质体上模拟酶的分布:凝血中表面介导反应的新框架。
Math Biosci. 2024 Aug;374:109229. doi: 10.1016/j.mbs.2024.109229. Epub 2024 Jun 6.
7
Factor V variants in bleeding and thrombosis.出血和血栓形成中的凝血因子V变体
Res Pract Thromb Haemost. 2024 Jan 26;8(1):102330. doi: 10.1016/j.rpth.2024.102330. eCollection 2024 Jan.
8
The unfolded protein response links ER stress to cancer-associated thrombosis.未折叠蛋白反应将内质网应激与癌症相关的血栓形成联系起来。
JCI Insight. 2023 Aug 31;8(19):e170148. doi: 10.1172/jci.insight.170148.
9
TMEM16E regulates endothelial cell procoagulant activity and thrombosis.TMEM16E 调节血管内皮细胞的促凝活性和血栓形成。
J Clin Invest. 2023 Jun 1;133(11):e163808. doi: 10.1172/JCI163808.
10
Cryo-EM structures of coagulation factors.凝血因子的冷冻电镜结构
Res Pract Thromb Haemost. 2022 Nov 2;6(7):e12830. doi: 10.1002/rth2.12830. eCollection 2022 Oct.